Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-cash Items for 10 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 85.71% to $50000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $50000.0, a 85.71% decrease, with the full-year FY2025 number at $50000.0, down 85.71% from a year prior.
  • Non-cash Items was $50000.0 for Q4 2025 at Intellia Therapeutics, down from $4.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $974.5 million in Q2 2021 to a low of $50000.0 in Q4 2025.
  • A 5-year average of $108.9 million and a median of $16.0 million in 2024 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 5815.27% in 2022; the steepest drop was 99.41% in 2022.
  • Intellia Therapeutics' Non-cash Items stood at $2.0 million in 2021, then soared by 62.63% to $3.2 million in 2022, then surged by 1016.73% to $35.9 million in 2023, then plummeted by 99.03% to $350000.0 in 2024, then plummeted by 85.71% to $50000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Non-cash Items are $50000.0 (Q4 2025), $4.1 million (Q3 2025), and $4.2 million (Q2 2025).